Specific cytoarchitectural areas, subfields, and even lamina develop Alzheimer pathological changes, while other are spared. A pattern of hierarchical vulnerability defines areas that are at risk. This proposal will test hypotheses about molecular characteristics that could underlie this pattern of vulnerability. Our previous studies show neurons that develop neurofibrillary tangles (NFT) occur mainly in specific lamina in limbic and association cortices. Senile plaques (SP) are found in a different but consistent hierarchical pattern, with some brain areas substantially more affected than others. We now propose to combine quantitative anatomic analyses of pathological changes, immunohistochemical and in situ hybridization studies, and RNA analyses from microdissected brain regions to examine how neurons that develop NFT differ from those that do not, and how regions that accumulate SP differ from those that are spared. In the first aim, we will pursue preliminary results which that a change occurs in AD in the pattern of tau isoforms expressed. The second and third aims focus on possible tau kinases. Recent studies show that the MAP Kinase (MAPK) family of Pro directed Ser/Thr kinases (ERKs) phosphorylate tau in vitro in a pattern resembling the changes that occur in NFT. We will study ERKs 1 and 2, ERK3 and the p54 MAPKs. We will test the hypothesis that p54 MAPK phosphorylates tau in a PHF tau fashion. Glycogen synthase kinase 3 has also been implicated in tau phosphorylation. These kinases are all highly expressed in brain, but the neuroanatomical regional and cellular distribution of their expression is unknown. We will study the normal patterns of their expression a swell as determine whether or not changes occur in neurons that develop NFT and in the microenvironment surrounding SP. Pilot experiments will be aimed at determining the activation status of these kinases in the AD brain.
In AIM 4, we continue our studies of molecules potentially related to SP formation. Our previous studies, in collaboration with Dr. Tanzi (project 4), analyzed expression of APP major splice forms and found no difference between AD and controls. We now turn to the anatomic distribution and expression of a novel isoform of APP, L-APP (lacking exon 15), as well as new members of the APP family, APLP1 and APLP2. We have observed that nitric oxide synthase neurons are spared in AD.
In Aim 5, in collaboration with Dr. Young, (project 1), we will determine the phenotype of these spared neurons in terms of tau, kinase, and glutamate receptor expression. In sum, the overall goal of this project will be to advance the profile of vulnerability from anatomical description towards molecular phenotype by generating profiles of tau, the newly described ERK family of protein kinases, and APP family members in vulnerable and spared areas and cells.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG011337-05
Application #
6098484
Study Section
Project Start
1998-04-01
Project End
2000-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Weissmiller, April M; Natera-Naranjo, Orlangie; Reyna, Sol M et al. (2015) A ?-secretase inhibitor, but not a ?-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One 10:e0118379
Liu, Qing; Waltz, Shannon; Woodruff, Grace et al. (2014) Effect of potent ?-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71:1481-9
Young, Anne B (2009) Four decades of neurodegenerative disease research: how far we have come! J Neurosci 29:12722-8
Swerdlow, N R; Young, A B (2001) Neuropathology in Tourette syndrome: an update. Adv Neurol 85:151-61
Cha, J H; Farrell, L A; Ahmed, S F et al. (2001) Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol Dis 8:90-102
Montine, T J; Shinobu, L; Montine, K S et al. (2000) No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Ann Neurol 48:950
Chin, J Y; Knowles, R B; Schneider, A et al. (2000) Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J Neuropathol Exp Neurol 59:966-71
Standaert, D G; Friberg, I K; Landwehrmeyer, G B et al. (1999) Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Brain Res Mol Brain Res 64:11-23
Knowles, R B; Chin, J; Ruff, C T et al. (1999) Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: implications for MAP kinase activation in Alzheimer disease. J Neuropathol Exp Neurol 58:1090-8
Montine, T J; Beal, M F; Robertson, D et al. (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 52:1104-5

Showing the most recent 10 out of 50 publications